Latest Articles about NVS

Positive Data on Novartis' Jakavi - Analyst Blog

Zacks Equity Research — Wed, 19 Jun 2013 01:30:54 Z

Novartis ( NVS ) recently presented positive results on oncology drug Jakavi from a three-year follow up analysis of a phase III trial, COMFORT II. It was observed that the overall

Positive Data on Incyte's Jakafi - Analyst Blog

Zacks Equity Research — Wed, 19 Jun 2013 00:30:23 Z

Incyte Corporation ( INCY ) recently announced positive long-term data from two ongoing studies on Jakafi. Incyte presented data from the studies at the 18th Congress of the European

Ariad's Iclusig in GIST Phase II Study - Analyst Blog

Zacks Equity Research — Wed, 19 Jun 2013 00:30:01 Z

Ariad Pharmaceuticals, Inc. ( ARIA ) recently announced the commencement of an open-label, multicenter phase II trial of Iclusig (ponatinib) in patients suffering from metastatic and/or

Good News for InterMune - Analyst Blog

Zacks Equity Research — Tue, 18 Jun 2013 00:30:01 Z

InterMune, Inc. ( ITMN ) recently received encouraging news when the pricing and reimbursement conditions for its sole marketed drug, Esbriet, were approved by the Board of the Italian Drug

These 2 Health Care Stocks Could Win Big With FDA's New 'Breakthrough' Status

mike-vodicka@streetauthority.com (Michael Vodicka) — Fri, 14 Jun 2013 19:00:00 Z

The Food and Drug Administration (FDA) made a groundbreaking policy change last year that is having a large impact on the biotech industry and creating a big opportunity for investors. To

PDL BioPharma Guides Higher 2Q Royalties - Analyst Blog

Zacks Equity Research — Thu, 13 Jun 2013 20:29:15 Z

PDL BioPharma Inc. ( PDLI ) recently announced that it expects to receive royalty revenues of around $143 million in second quarter 2013, up 14% from the royalties earned in the second

Questcor Surges on Drug Acquisition - Analyst Blog

Zacks Equity Research — Wed, 12 Jun 2013 18:28:44 Z

Shares of Questcor Pharmaceuticals, Inc. ( QCOR ) recently received a major boost when the company announced the acquisition of development and commercialization rights to Synacthen and

Encouraging Data on Novartis Candidate - Analyst Blog

Zacks Equity Research — Tue, 11 Jun 2013 00:26:51 Z

Novartis ( NVS ) recently released encouraging data on its pipeline candidate, LDK378, from a phase I study (n=114). We note that Novartis is developing LDK378 for the treatment of

Actavis Challenges Patents - Analyst Blog

Zacks Equity Research — Mon, 10 Jun 2013 19:50:01 Z

Actavis, Inc. ( ACT ) recently announced that it is seeking FDA approval for its generic versions of Fresenius Kabi's Diprivan and Bayer's ( BAYRY ) Safyral. While Diprivan is an

Positive Data on Novartis' Afinitor - Analyst Blog

Zacks Equity Research — Sat, 08 Jun 2013 02:28:12 Z

Novartis ( NVS ) recently announced positive results on Afinitor, from a phase III trial, BOLERO-3 (Breast cancer trials of OraL EveROlimus-3). The study evaluated Novartis' Afinitor plus

FDA Issues Warning Letter to Novartis - Analyst Blog

Zacks Equity Research — Thu, 06 Jun 2013 02:29:19 Z

Novartis ( NVS ) recently announced that the US Food and Drug Administration (FDA) issued a warning letter to the company's generic arm, Sandoz, regarding its Austrian manufacturing site,

CHMP Positive on Novartis' Lucentis - Analyst Blog

Zacks Equity Research — Wed, 05 Jun 2013 02:26:04 Z

Novartis ( NVS ) recently received encouraging news when it obtained a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for an additional indication for

FDA Accepts Teva sNDA - Analyst Blog

Zacks Equity Research — Sat, 01 Jun 2013 02:26:37 Z

Teva Pharmaceutical Industries Ltd. ( TEVA ) recently announced that its supplemental new drug application (sNDA) for its thrice-weekly dosing regimen of Copaxone has been accepted for

Setback for Valeant Pharma - Analyst Blog

Zacks Equity Research — Thu, 30 May 2013 02:29:48 Z

Valeant Pharmaceuticals ( VRX ) recently suffered a setback when the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to the company regarding its New Drug

Encouraging Data from Novartis - Analyst Blog

Zacks Equity Research — Thu, 30 May 2013 00:31:38 Z

Novartis ( NVS ) recently announced encouraging data on diabetes drug Galvus (vildagliptin) from a large multi-center randomized trial, INTERVAL study (n=278). The 24-week study